ClinicalTrials.gg
CompletedNCT02833948GALILEO-4DUpdated Jan 18, 2020Results posted

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

A Phase 3 interventional study of Acetylsalicylic acid and Clopidogrel in Aortic Valve Stenosis, Cardiovascular Diseases and Heart Valve Diseases, sponsored by ECRI bv. Completed at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by ECRI bv · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Enrollment
45th of 93
231 · median 220
Started
2016
with 12 others
Phase 3
6 of 191
3 open now
Registered
79th of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 45th largest by enrollment of the 93 interventional ones that give a count, is one of 13 that started in 2016, is one of 6 in phase 3, and was the 79th registered.

Aortic Valve Stenosis

1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

The aortic valve is located between the left ventricle and the aorta. Patients with symptomatic, severe aortic valve stenosis conventionally have it surgically replaced requiring direct access to the heart through the chest. Transcatheter aortic valve replacement (TAVR) is now a well-established alternative for treating severe aortic valve stenosis. Both types of intervention improve prognosis and alleviate symptoms.

The optimal choice of blood thinning therapy after TAVR is unknown. It has been reported that leaflet thrombosis with reduced leaflet motion can occur and this phenomenon has been suggested to be potentially related with neurological events. In addition, the occurence of this phenomenon can be reduced with anticoagulation blood thinning therapy.

The purpose of this study is to evaluate if anticoagulation compared to the usual double platelet inhibitor therapy after TAVR can reduce the risk of leaflet thrombosis.

Read the detailed description

BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become an established therapeutic option for patients with symptomatic, severe aortic valve stenosis, who are ineligible or at high risk for conventional surgical aortic valve replacement (SAVR). It was recently reported that leaflet thickening and reduced leaflet motion, verified by four-dimensional computed tomography (4DCT), was not uncommon after both TAVR and SAVR. It has been emphasized that this phenomenon should be further investigated for its effect on clinical outcomes (e.g. stroke) and valve durability. As this valve leaflet thickening and reduced motion could be reversed by oral anticoagulant (OAC) treatment and was not observed in patients on chronic OAC therapy, it has been hypothesized that this phenomenon could be related to possible leaflet thrombosis or a "thrombotic film" on the leaflets.

AIM: To evaluate whether a rivaroxaban-based strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing subclinical valve leaflet thickening and motion abnormalities - as detected by 4DCT-scan.

POPULATION: All patients undergoing successful TAVR by ileofemoral or subclavian access with an approved TAVR device will be screened for eligibility. Included subjects must provide written informed consent. Inclusion and exclusion criteria are listed below.

DESIGN: The GALILEO-4D trial will be conducted as a substudy of the multicenter, open-label, randomized, event-driven, active-controlled GALILEO trial. Patients will be 1:1 randomized to an antiplatelet-based strategy vs. rivaroxaban-based strategy - the randomization will adopt the same 1:1 randomization of the main GALILEO trial. In case the GALILEO-4D trial should still be continued after completion of the main GALILEO trial, this 1:1 randomization will be continued until inclusion of 150 patients in both treatment groups. In total, 300 patients will be randomized in the GALILEO-4D trial.

INTERVENTION: Subjects in the GALILEO-4D substudy will receive the same intervention as in the main GALILEO study. In addition, a 4DCT-scan and echocardiography will be performed at 90 days after randomization.

END POINTS: The primary endpoint constitutes the rate of patients with at least one prosthetic leaflet with > 50% motion reduction as assessed by cardiac 4DCT-scan (total N = 300). The secondary endpoints are listed below.

03

Conditions studied

  • Aortic Valve Stenosis
  • Cardiovascular Diseases
  • Heart Valve Diseases
  • Ventricular Outflow Obstruction
  • Thrombosis

Keywords

  • Heart Valve Disease
  • Randomized Controlled Trial
  • Transcatheter Aortic Valve Replacement
  • TAVR
  • Valve Thrombosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successful TAVR of a native aortic valve stenosis
  • By iliofemoral or subclavian access
  • With any approved/marketed TAVR device
  • Written

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation (AF), current or previous, with an ongoing indication for oral anticoagulant treatment
  • Any other indication for continued treatment with any oral anticoagulant
  • Known bleeding diathesis (such as but not limited to count ≤ 50,000/mm3 at screening, level \< 8.5 g/dL or \< 5.3 mmol/l, history of intracranial hemorrhage, or subdural hematoma)
  • Any indication for dual antiplatelet therapy (DAPT) for more than three months after randomization (such as coronary, carotid, or peripheral stent implantation)
  • Clinically overt stroke within the last three months
  • Planned coronary or vascular intervention or major surgery
  • Severe renal insufficiency ( \< 30 mL/min/1.73 m2) or on dialysis, or post-TAVR unresolved acute kidney injury with renal dysfunction ≥ stage 2
  • Moderate and severe hepatic impairment ( Class B or C) or any hepatic disease associated with coagulopathy
  • Iodine contrast allergy or other condition that prohibits CT imaging
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
231 participants (actual)

Study arms

  • Active comparator
    ASA + Clopidogrel

    ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy

    Drug: Acetylsalicylic acid · Drug: Clopidogrel

  • Experimental
    Rivaroxaban + ASA

    Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy

    Drug: Acetylsalicylic acid · Drug: Rivaroxaban

Interventions

  • Drug: Acetylsalicylic acid: 75 - 100 mg OD (for first 90 days only in arm 1)

    Also known as: Asprin

  • Drug: Clopidogrel 75 mg OD for first 90 days

    Also known as: Plavix

  • Drug: Rivaroxaban (Xarelto): 10 mg OD (once-daily)

    Also known as: Xarelto

06

What researchers measure

Primary outcomes

  1. Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan

    Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (\<50%), (III) moderate to severely reduced (\>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is \> 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.

    Time frame: 3 months

Secondary outcomes

  1. The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan

    The rate of prosthetic leaflets with RLM\> grade 3 as assessed by cardiac 4DCT

    Time frame: 3 months

  2. The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan

    The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.

    Time frame: 3 months

  3. The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan

    The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan

    Time frame: 3 months

  4. Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.

    Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization. scale \[0-100\]

    Time frame: 3 months

  5. Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.

    Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization. scale \[0.1-4.0\]

    Time frame: 3 months

  6. Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.

    Death, Dichotomization by HALT

    Time frame: 3 months

  7. Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.

    Death, Dichotomization by RLM

    Time frame: 3 months

  8. Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.

    Thromboembolic event, Dichotomization by HALT

    Time frame: 3 months

  9. Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.

    Thromboembolic event, Dichotomization by RLM

    Time frame: 3 months

07

Results

Posted Jan 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneASA + ClopidogrelRivaroxaban + ASA
Started116115
Completed10197
Not completed1518
Withdrew: Death23
Withdrew: Were not scanned813
Withdrew: Scans could not be evaluated52

Outcome measures

PrimaryRate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan

Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (\<50%), (III) moderate to severely reduced (\>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is \> 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.

Time frame:
3 months
Reported as:
Count of participants · Participants
Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan
ParticipantsASA + ClopidogrelRivaroxaban + ASA
Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan112
Statistical analysis
  • ASA + Clopidogrel vs Rivaroxaban + ASA · Fisher Exact · p = 0.01The Fisher's exact probability test was used to compare the percentages of patients with the primary end point between the treatment groups.
SecondaryThe Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan

The rate of prosthetic leaflets with RLM\> grade 3 as assessed by cardiac 4DCT

Time frame:
3 months
Reported as:
Number · leaflets
The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan
leafletsASA + ClopidogrelRivaroxaban + ASA
The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan143
SecondaryThe Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan

The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.

Time frame:
3 months
Reported as:
Count of participants · Participants
The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan
ParticipantsASA + ClopidogrelRivaroxaban + ASA
The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan3312
SecondaryThe Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan

The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan

Time frame:
3 months
Reported as:
Number · Leaflets
The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan
LeafletsASA + ClopidogrelRivaroxaban + ASA
The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan5316
SecondaryAortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.

Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization. scale \[0-100\]

Time frame:
3 months
Reported as:
Mean · mm Hg
Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.
mm HgASA + ClopidogrelRivaroxaban + ASA
Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.10 ± 510 ± 5
Statistical analysis
  • ASA + Clopidogrel vs Rivaroxaban + ASA · Fisher Exact · p = 0.01
SecondaryEffective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.

Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization. scale \[0.1-4.0\]

Time frame:
3 months
Reported as:
Mean · cm2
Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.
cm2ASA + ClopidogrelRivaroxaban + ASA
Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.1.8 ± 0.41.8 ± 0.5
SecondaryDeath Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.

Death, Dichotomization by HALT

Time frame:
3 months
Reported as:
Count of participants · Participants
Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.
ParticipantsHALT (-)HALT (+)
Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.00
SecondaryDeath Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.

Death, Dichotomization by RLM

Time frame:
3 months
Reported as:
Count of participants · Participants
Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.
ParticipantsRLM>2 (-)RLM(+)
Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.00
SecondaryThromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.

Thromboembolic event, Dichotomization by HALT

Time frame:
3 months
Reported as:
Count of participants · Participants
Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.
ParticipantsHALT (-)HALT (+)
Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.20
SecondaryThromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.

Thromboembolic event, Dichotomization by RLM

Time frame:
3 months
Reported as:
Count of participants · Participants
Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.
ParticipantsRLM>2 (-)RLM(+)
Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.20

Adverse events

Collected over 90 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ASA + Clopidogrel2/116 (1.7%)3/116 (2.6%)17/116 (14.7%)
Rivaroxaban + ASA3/115 (2.6%)7/115 (6.1%)16/115 (13.9%)
Most frequent serious events
Most frequent serious events
EventASA + ClopidogrelRivaroxaban + ASA
Major bleeding eventBlood and lymphatic system disorders1/1164/115
Thromboembolic eventCardiac disorders2/1164/115
Most frequent other events
Most frequent other events
EventASA + ClopidogrelRivaroxaban + ASA
minor bleedingBlood and lymphatic system disorders17/11616/115

Baseline characteristics

Age, Continuous
Age, Continuous(years)ASA + ClopidogrelRivaroxaban + ASATotal
Mean80.5 ± 6.279.7 ± 7.380.1 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)ASA + ClopidogrelRivaroxaban + ASATotal
Female424183
Male7474148
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ASA + ClopidogrelRivaroxaban + ASATotal
Count of participants——0
Body-mass index
Body-mass index(kg/m^2)ASA + ClopidogrelRivaroxaban + ASATotal
Mean27.8 ± 5.127.7 ± 6.527.8 ± 5.8
Hypertension
Hypertension(Participants)ASA + ClopidogrelRivaroxaban + ASATotal
Count of participants9598193
Diabetes Mellitus
Diabetes Mellitus(Participants)ASA + ClopidogrelRivaroxaban + ASATotal
Count of participants272148
STS risk score
STS risk score(%)ASA + ClopidogrelRivaroxaban + ASATotal
Mean3.0 ± 2.12.8 ± 1.52.9 ± 1.8
STS risk category - High
STS risk category - High(Participants)ASA + ClopidogrelRivaroxaban + ASATotal
Count of participants314

20 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Mount Sinai M.C
    New York, New York 10029-6574, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas, Health Science Center
    Houston, Texas 78229, United States
  • University of Alberta Hospital
    Edmonton, AB T6G 2B7, Canada
  • Providence Health Care
    Vancouver, ON M1L 1W1, Canada
  • Aarhus university hospital
    Aarhus, 8000, Denmark
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Odense University Hospital
    Odense, 5000, Denmark
  • Kerckhoff Klinik GmbH
    Bad Nauheim, 61231, Germany
  • Charité- Universitätsmedizin Berlin - Campus Mitte
    Berlin, 10117, Germany
  • Deutsches Herzzentrum Berlin
    Berlin, 13353, Germany
  • St. Johannes Hospital
    Dortmund, 44137, Germany
  • Universitätsklinikum Erlangen
    Erlangen, 91012, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Medicin Herzzentrum Lahr/Baden
    Lahr, 77933, Germany
  • Herzzentrum Leipzig - Universitätsklinik
    Leipzig, 04289, Germany
  • Deutsches Herzzentrum München
    München, 80636, Germany
  • Academic Medical Center
    Amsterdam, 1105, Netherlands
  • Amphia Zienkenhuis
    Breda, 4818, Netherlands
  • Erasmus M.C
    Rotterdam, 3015, Netherlands
  • Skåne University Hospital
    Lund, SE-205 02, Sweden
  • Karolinska University Hospital
    Stockholm, SE-171 76, Sweden
  • University Hospital Basel
    Basel, 4056, Switzerland
  • Inselspital
    Bern, 3010, Switzerland
09

References and documents

Publications

  • Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, Sondergaard L. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med. 2015 Nov 19;373(21):2015-24. doi: 10.1056/NEJMoa1509233. Epub 2015 Oct 5. PubMed 26436963 ↗
  • De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, Kini AS, Veien KT, Abdel-Wahab M, Kim WK, Balan P, Van Mieghem N, Mathiassen ON, Jeger RV, Arnold M, Mehran R, Guimaraes AHC, Norgaard BL, Kofoed KF, Blanke P, Windecker S, Sondergaard L; GALILEO-4D Investigators. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020 Jan 9;382(2):130-139. doi: 10.1056/NEJMoa1911426. Epub 2019 Nov 16. PubMed 31733182 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Dec 2018 and a completion of Mar 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2016
First posted
Jul 14, 2016
Start
May 2016
Primary completionActual
Dec 2018
CompletionActual
Mar 6, 2019
Results first posted
Jan 18, 2020
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02833948
Lead sponsor
ECRI bv
Collaborators
Rigshospitalet, Denmark, Bayer, Cardialysis BV
Responsible party
Sponsor
First posted
Jul 14, 2016
Start date
May 2016
Primary completion
Dec 2018
Completion
Mar 6, 2019
Results posted
Jan 18, 2020
Last update
Jan 18, 2020

Study contacts

Lars Søndergaard, MD;DMSc
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion